Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOXORUBICIN Cause Disease recurrence? 980 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 980 reports of Disease recurrence have been filed in association with DOXORUBICIN (Doxorubicin Hydrochloride). This represents 1.2% of all adverse event reports for DOXORUBICIN.

980
Reports of Disease recurrence with DOXORUBICIN
1.2%
of all DOXORUBICIN reports
200
Deaths
126
Hospitalizations

How Dangerous Is Disease recurrence From DOXORUBICIN?

Of the 980 reports, 200 (20.4%) resulted in death, 126 (12.9%) required hospitalization, and 27 (2.8%) were considered life-threatening.

Is Disease recurrence Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOXORUBICIN. However, 980 reports have been filed with the FAERS database.

What Other Side Effects Does DOXORUBICIN Cause?

Febrile neutropenia (8,844) Off label use (7,858) Disease progression (6,165) Neutropenia (5,891) Drug ineffective (4,598) Pyrexia (3,697) Thrombocytopenia (3,638) Anaemia (3,601) Product use in unapproved indication (3,502) Nausea (2,925)

What Other Drugs Cause Disease recurrence?

NIRMATRELVIR\RITONAVIR (20,040) PREDNISONE (1,979) CYCLOPHOSPHAMIDE (1,689) RITUXIMAB (1,588) METHOTREXATE (1,401) VINCRISTINE (932) PREDNISOLONE (873) MYCOPHENOLATE MOFETIL (852) DEXAMETHASONE (784) CARBOPLATIN (775)

Which DOXORUBICIN Alternatives Have Lower Disease recurrence Risk?

DOXORUBICIN vs DOXYCYCLINE DOXORUBICIN vs DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYCYCLINE\DOXYCYCLINE HYCLATE DOXORUBICIN vs DOXYLAMINE DOXORUBICIN vs DOXYLAMINE\PYRIDOXINE

Related Pages

DOXORUBICIN Full Profile All Disease recurrence Reports All Drugs Causing Disease recurrence DOXORUBICIN Demographics